FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
PLAINSBORO, N.J., March 15, 2017 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, announced the launch of the Titan™ Press-Fit Reverse Shoulder for Fracture.
The use of the reverse shoulder to treat humeral fractures has increased in recent years. However, heat from cement used to secure the prosthesis can hinder healing of the bone, which negatively impacts patient outcomes.1 The Titan reverse is one of the few prostheses that does not require cement, due to its unique two-piece stem that achieves a direct implant-to-bone press-fit fixation below the fracture line in the humeral canal.
Stems that fixate in the humeral canal have a strong clinical heritage, with published literature showing comparable or better functional results in fracture scenarios compared to published studies of other stem designs.2
Matt Ramsey, MD, of the Rothman Institute said, “This product has revolutionized my treatment of proximal humeral fractures. The Titan Press-Fit Reverse allows me to reliably obtain a solid fit in the canal without having to wait for the cement to dry, and the ability to adjust height and version independent of the stem means no fiddling with a jig or making sacrifices on the fit.”
The Titan Press-Fit Reverse for Fracture was developed in conjunction with Matthew Ramsey, MD; William Geissler, MD; Sanford Kunkel, MD; Jean-Marc Glasson, MD; Phillip Duke, MBBS, FRACS, FA(ORTH)A; and Mark Ross, MBBS, FRACS, FA(ORTH)A.
“The Titan Press-Fit Reverse for Fracture is a cornerstone of our shoulder portfolio. At Integra, we’re committed to creating products that enhance patient care and enrich the surgeon experience. Our shoulder franchise is poised to redefine expectations in shoulder arthroplasty with this and other products we have in the pipeline,” said Bob Davis, president of Integra’s Orthopedics & Tissue Technologies division.
About Integra
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
For additional information on the release of the Titan™ Modular Shoulder System Press-Fit Reverse for Fracture, please contact [email protected].
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
1 Formaini, NT, Everding, NG, Levy, JC, Rosas, S. Tuberosity healing after reverse shoulder arthroplasty for acute proximal humerus fractures: the “black and tan” technique. J Shoulder Elbow Surg 2015 Nov;24(11):e299-306. doi: 10.1016/j.jse.2015.04.014. Epub 2015 Jul 2.
2 Ross, M, Hope, B, Stokes, A, Peters, SE, McLeod, I, Duke, PFR. Reverse Shoulder Arthroplasty for the treatment of three-part and four-part proximal humeral fractures in the elderly. J Shoulder Elbow Surg 2015 Feb;24(2):215-22. doi: 10.1016/j.jse.2014.05.022. Epub 2014 Aug 29.
CONTACT: Integra LifeSciences Holdings Company Investors Angela Steinway 609-936-2268 [email protected] Michael Beaulieu 609-750-2827 [email protected] Media Laurene Isip 609-750-7984 [email protected]
